Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac's COVID-19 vaccine induces quick immune response - study

11/17/2020 | 08:27pm EST

* Sinovac releases results from Phase I/II vaccine trials

* Sinovac's CoronaVac appears safe and well tolerated

* Late-stage trials to determine vaccine efficacy ongoing

SINGAPORE/BEIJING, Nov 18 (Reuters) - Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.

While the early to mid-stage trials were not designed to assess the efficacy of CoronaVac, researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.

The study comes hot on the heels of upbeat news this month from U.S. drugmakers Pfizer and Moderna as well as Russia that showed their experimental vaccines were over 90% effective based on interim data from large, late-stage trials.

CoronaVac and four other experimental vaccines developed in China are currently undergoing late-stage trials to determine their effectiveness in preventing COVID-19.

The Sinovac findings, published in a peer-reviewed paper in medical journal The Lancet Infectious Diseases, came from results in Phase I and Phase II clinical trials in China involving more than 700 participants.

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval," Zhu Fengcai, one of the authors of the paper, said.

"We believe that this makes the vaccine suitable for emergency use during the pandemic," Zhu said in a statement published alongside the paper.

Researchers said the findings from large, late-stage studies, or Phase III trials, would be crucial to determine if the immune response generated by CoronaVac was sufficient to protect people from the coronavirus infection.

Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.

The results must be interpreted with caution until Phase III results are published, Naor Bar-Zeev, a professor from Johns Hopkins University who was not involved in the study, said.

"But even then, after Phase III trial completion and after licensure, we should prudently remain cautious," he said.


CoronaVac is one of three experimental COVID-19 vaccines China has been using to inoculate hundreds of thousands of people under an emergency use programme.

The two other vaccines in China's emergency programme, both developed by institutes linked to Sinopharm, and another vaccine from CanSino Biologics, were also shown to be safe and triggered immune responses in early and mid-stage trials, peer-reviewed papers show.

Gang Zeng, a Sinovac researcher involved in the CoronaVac study, said the vaccine could be an attractive option because it can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (36°-46°F) and may remain stable for up to three years.

"(It) would offer some advantages for distribution to regions where access to refrigeration is challenging," the author said.

Vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.

Pfizer's vaccine must be stored and transported at -70C though it can be kept in a normal fridge for up to five days, or up to 15 days in a thermal shipping box. Moderna's candidate is expected to be stable at normal fridge temperatures for 30 days but for storage of up to six months it needs to be kept at -20C.

CoronaVac is also being considered by Brazil and Indonesia for inoculations in the coming months.

Indonesia has sought emergency authorisation to start a mass vaccination campaign by the end of the year and vaccines produced by Sinovac and China's Sinopharm are slated to be used in the early stages of the campaign.

Brazil's Sao Paulo also plans to roll out CoronaVac as early as January and has agreed a supply deal with Sinovac.

"The excellent safety of CoronaVac, compared to other vaccines under development, makes for greater acceptance by the population," Ricardo Palacios, trial manager of Brazil's Butantan Institute biomedical centre, which is testing CoronaVac, told Reuters.

(Reporting by Miyoung Kim in Singapore and Roxanne Liu in Beijing; Additional reporting by Anthony Boadle in Brasilia; Editing by David Clarke and Himani Sarkar)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CANSINO BIOLOGICS INC. -3.92% 235 End-of-day quote.33.14%
MODERNA, INC. -5.21% 122.91 Delayed Quote.24.10%
SINOPHARM GROUP CO., LTD. 1.90% 19.26 End-of-day quote.2.12%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
01/18Philippines to buy 20 mln doses of Moderna's COVID-19 vaccine
01/18Sinovac says its COVID-19 vaccine more effective with longer dosing interval
01/18SINOVAC BIOTECH : Brazil vaccinations start as country faces vaccine ingredient ..
01/18SINOVAC BIOTECH : Brazil to begin vaccination campaign on Monday afternoon
01/17ASTRAZENECA : Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shot..
01/17ASTRAZENECA : Brazil regulator to decide on emergency use of Sinovac, AstraZenec..
01/16SINOVAC BIOTECH : Indonesia reports record daily increase in COVID-19 cases
01/15SINOVAC BIOTECH : Brazil airlifts emergency oxygen into pandemic-struck state, v..
01/14WRAPUP 1-China steals march on West in developing nations' vaccine rollout
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 34,7%
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-5.54%93 519
BIOGEN INC.12.65%42 447